For Non-US Residents
are several ways to manage Parkinson’s disease (PD). They include
non-drug treatments, such as physical therapy, occupational therapy
and dietary management; surgery such as a pallidotomy (removal of
a part of the brain called the globus pallidus), thalamotomy (removal
of part of the thalamus), or deep brain stimulation; and drug, or
pharmacological treatment. At present, there is no cure for Parkinson’s
disease. Management of Parkinson’s disease relieves symptoms but
does not cure it.
Drug therapies for PD
There are many drugs that can be effective for Parkinson’s disease, although
effectiveness differs for every patient depending on the stage of the disease,
how long the drug has been used, and other factors. Side effects may prevent
doctors from recommending the most effective dose, or they may require a new
drug to counteract them.
Six categories of drugs are currently used to treat PD:
Currently, the best treatments for PD involve the use of drugs such as levodopa.
Alternative therapies include acupuncture, massage, yoga, and other therapies.
These can help relieve some symptoms of the disease and loosen tight muscles.
Alternative practitioners have also applied herbal and dietary therapies to
the treatment of PD.
You’ll want to check with your doctor to find out more about which alternative therapies might be right for you.
TASMAR SHOULD NOT BE USED BY PATIENTS UNTIL THERE HAS BEEN A COMPLETE DISCUSSION OF THE RISKS AND THE PATIENT HAS PROVIDED WRITTEN INFORMED CONSENT (SEE PATIENT ACKNOWLEDGEMENT FORM).
WARNING: Because of the risk of potentially fatal, acute fulminant liver failure, TASMAR (tolcapone) should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies (see INDICATIONS and DOSAGE AND ADMINISTRATION sections).
TASMAR therapy should not be initiated if the patient exhibits clinical evidence of liver disease or two SGPT/ALT or SGOT/AST values greater than the upper limit of normal. Patients with severe dyskinesia or dystonia should be treated with caution (see PRECAUTIONS: Rhabdomyolysis).
Laboratory Tests: Although a program of frequent laboratory monitoring for evidence of hepatocellular injury is deemed essential, it is not clear that periodic monitoring of liver enzymes will prevent the occurrence of fulminant liver failure. However, it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery. Accordingly, the following liver monitoring program is recommended.
Please see accompanying complete prescribing information including BOXED warning.
TASMAR® is a registered trademark of Valeant Pharmaceuticals International